Rectal cancer patients may benefit by receiving chemotherapy first
Rectal cancer patients may benefit by receiving chemotherapy first
15 May 2014
Rectal cancer patients may tolerate treatment if they receive chemotherapy before radiation therapy and surgery, as new research shows it may be more tolerable.
In the study, reordering the regimen that way enabled all but six of 39 patients to undergo a full course of standard treatment for rectal cancer. The research results will be presented at the American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
Only 6 in 10 comply with chemotherapy after surgery
Studies have shown that only about 60% of rectal cancer patients comply with postoperative chemotherapy, said lead researcher Dr. Kimberly Perez, assistant professor of medicine in the Warren Alpert Medical School of Brown University and a cancer physician at Rhode Island Hospital. In the phase 2 trial, "Complete Neoadjuvant Therapy in Rectal Cancer" (CONTRE), more than 90% of the patients were able to complete a regimen of mFOLFOX6 when it was moved to the front of the line.
"The thought was, what can we do to make it more tolerable and get the benefit that we wanted," said Perez. "It's encouraging because we were able to get the numbers up of patients who were able to get all the chemotherapy indicated."
"It's encouraging because we were able to get the numbers up of patients who were able to get all the chemotherapy indicated."All but one patient in the study underwent surgery and 85% underwent the middle step of chemoradiation after completing chemotherapy. The vast majority therefore received all three courses of standard treatment, albeit in a new order.
Almost all of the patients came into the study with rectal bleeding, but that symptom abated for all of them during treatment, Perez said.
Results after treatment regimen
Regarding the cancer itself, a majority of patients, 32 of whom entered the trial at stage 3 and seven of whom were less advanced at stage 2, responded at least to some degree to the induction chemotherapy and chemoradiation treatments. By the time they got to surgery, 13 patients had no tumor left ("pathologic complete response"), 10 got all the way back to stage 1, seven were at stage 2, and eight remained at stage 3.
The study occurred too recently, however, to provide a measure of overall survival, Perez acknowledged. The last patient finished surgery in January 2014.
The rate of side effects such as neutropenia, an adverse impact on the immune system, was not unusual.
The results of the CONTRE trial are now feeding into the development of a new national rectal cancer trial spearheaded by NRG Oncology, Perez said. That protocol will involve chemo first, then chemoradiation with biological anti-cancer agents, and finally surgery. Brown Univeristy Oncology Group and the Cancer Center of Rhode Island Hospital and associated satellites will be one of the study sites, Perez said.
Source: Science Daily: http://www.sciencedaily.com/releases/2014/05/140515113332.htm